Jiangsu Hengrui Pharmaceuticals Co. $600276.SS, recognized as China’s most valuable pharmaceutical company by market capitalization, recorded a remarkable performance during its recent Hong Kong listing. The company secured 9.9 billion Hong Kong dollars (HKD), equivalent to 1.3 billion US dollars (USD), through an initial public offering characterized by intense demand. Shares jumped by 25% on Friday, reaching HKD 55.15 and marking a robust start after the offering was priced at the high end of the marketed range.